TCF4 was mutant in two MAPK-B tumors and one MAPK-C tumor, and involved in a fusion in a BRAFV600E-mutant MAPK-A tumor (Fig. 2, Supplementary Data 1, 2). Here, TCF4 is linked to neoplasm.